Detailed Narrative
Q3 FY26 Financial Performance Overview
Aarti Pharmalabs reported a challenging Q3 FY26 with revenue at ₹425 crores, a decline from ₹471 crores in the prior year. EBITDA also saw a reduction to ₹103 crores from ₹115 crores, and Profit After Tax (PAT) significantly decreased to ₹44 crores from ₹74 crores YoY. The company declared an interim dividend of ₹1.5 per share. A notable factor impacting Q3 financials was ₹49 crores worth of goods in transit that could not be booked as sales, which would have increased revenue and PBT by ₹19 crores if recognized.
Segmental Performance and Outlook
The Xanthine Derivatives segment contributed 49% to Q3 turnover, with 51% from exports. The API and Intermediates business accounted for 39% of turnover, facing continued margin pressure. The CDMO/CMO segment contributed 12% of revenue, working with 21 customers on 59 active projects, of which 40 are commercial. Management expects API business to see new launches in 2026, particularly in oncology, and anticipates 2026-27 to be a better year for API overall.
Expansion Projects Update: Atali and Xanthine
The Atali plant commenced production of qualifying batches in Q3 FY26. However, initial operational hiccups, attributed to newer staff and plant nature, impacted production. Corrective actions are underway, with resolution expected by the end of Q4 FY26. The Xanthine expansion is on track for mechanical completion by March '26, with incremental capacity becoming available in Q1 FY27. The company aims for 50-60% overall utilization of the expanded Xanthine capacity within a year.
Capital Expenditure and Debt Profile
The company has capitalized approximately ₹300 crores for the Atali plant, with a total project outlay of ₹450 crores, and the balance of certain second-phase work is expected to complete in the coming months⏳. An additional ₹150 crores is allocated for Xanthine expansion across both sites. Gross debt stands at ₹650 crores, with net debt also around ₹650 crores. The management targets a net debt to equity ratio of 0.3 to 0.35 by Q4 FY26.
Xanthine Market Dynamics and Pricing
A significant development is China's decision to withdraw the 13% rebate on caffeine and its salts, which is expected to lead to an 8-10% price increase for Aarti Pharmalabs' Xanthine products. This, coupled with a 20% duty on Chinese products in the US market, positions Aarti favorably. The company is currently operating Xanthine at around 500 tonnes per month and aims to reach 800 metric tonnes per month post-expansion, with a target of 85-90% utilization of its 9,600 tonnes annual capacity by FY28.
Revised FY26 Outlook and FY27 Targets
For the full year FY26, EBITDA is expected to be largely in line with the previous year, with only marginal growth, a revision attributed to delays in Atali plant stabilization and softness in the API business. While specific FY27 guidance will be provided post-budgeting, management confirmed an analyst's target of ₹1,000 crores for CDMO sales in FY27. The company also aims to restore API quarterly run rates to ₹200 crores in the next couple of quarters.